Shanghai Jiao Tong University School of Medicine - Yale University Institute of Immune Metabolism

Shanghai Jiao Tong University School of Medicine - Yale University Institute of Immune Metabolism (SYIIM) was founded in 2019. Professor Richard A. Flavell (a member of the National Academy of Sciences, a member of the Royal Academy of Sciences, and a member of the American Academy of Medicine) and Professor Bing Su, the director of the Shanghai Institute of Immunology, are Co-directors of the institute.

Yale University is one of the most famous universities in the world. The Department of Immunobiology at Yale University School of Medicine was founded in 1988, and Professor Richard Flavell is the founding director of the department. Over a period of three decades, the department of immunobiology has become world leader in the study of basic immunologic mechanism, immune cell development and immune regulation, contributing several discoveries in new areas including the prediction and discovery in the innate immune system.

Since 2012, Professor Su Bing has been the director of the Shanghai Institute of Immunology from Yale University's Department of Immunobiology. He actively promoted discipline construction and international exchanges, continuously strengthened cooperation with the Department of Immunobiology of Yale University School of Medicine.

Under the efforts of Professor Bing Su and Professor Richard A. Flavell, as the first entity research institute established by Yale University outside the United States, SYIIM aims to become a world-class immune metabolism research center, focusing on immune cell metabolism regulation mechanism and application research and look forward to breakthroughs in key issues in the field of immune metabolism.

See more details

National Center for Translational Medicine·Shanghai

——National Key Scientific Infrastructure for Translational Medicine

National Center for Translational Medicine·Shanghai (the Center for short hereinafter), which is a national key scientific infrastructure, was approved to be founded by National Development and Reform Commission in July 2013 and put into full operation in December 2020. As a national academic institution, the Center is co-administrated by Ministry of Education and Shanghai Municipal Government.

With an aim to promote the translation of frontier technologies and the findings of basic medical research into clinical practices, the Center has adopted a “systematic three by three” research scheme. Guided by the National Innovation Strategies and National Mid- and Long-Term Guidelines for Scientific Development, and to make the best of the advantages of Shanghai Jiao Tong University and Rui-Jin Hospital, the research of the Center is focused on three major types of life-threatening diseases: cancer, cardiovascular and cerebrovascular diseases, and metabolic diseases. To carry out the research, the Center prioritized building three main systems: translational research core facilities, a resource sharing system, and a key technical supporting system.

Through the building-up of 6 platforms, namely, biobank, in-depth clinical resources analysis platform, biomarker and new drug discovery platform, diagnostic reagents and new medical instrument development platform, pathological study and molecular imaging platform, the Center serves as a systematic and integrated platform for bed-bench-bed translational research.

The core facility of the Center, the newly inaugurated clinical research building of Rui-Jin Hospital, accommodates 300 research wards of international standard which are designed for large-scale, prospective and standard Phase 0-IV clinical trials to promote the application of new therapies, technologies and agents in clinical practices.

Presently, a high-level and multidisciplinary research team has been established in the Center.

See more details